SCI
GapsinGuideline-ConcordantUseofDiagnosticTestsAmongLungCancerPatients背景
Theprevalenceofmalignantpleuraleffusionisincreasingworldwide,butprognosticbiomarkerstoplantreatmentandtounderstandtheunderlyingmechanismsofdiseaseprogressionremainunidentified.ThePROMISEstudywasdesignedwiththeobjectivestodiscover,validate,andprospectivelyassessbiomarkersofsurvivalandpleurodesisresponseinmalignantpleuraleffusionandbuildascorethatpredictssurvival.
恶性胸腔积液的患病率在世界范围内不断增加，但用于制定治疗计划和了解疾病进展潜在机制的预后生物标志物仍然不明。PROMISE研究的目的是发现，验证和前瞻性评估恶性胸腔积液的预后和胸膜固定术反应的生物标志物，并建立一个预测生存期的评分。
方法
Inthismulticohortstudy,weusedfiveseparateandindependentdatasetsfromrandomisedcontrolledtrialstoinvestigatepotentialbiomarkersofsurvivalandpleurodesis.Massspectrometry-baseddiscoverywasusedtoinvestigatepleuralfluidsamplesfordifferentialproteinexpressioninpatientsfromthediscoverygroupwithdifferentsurvivalandpleurodesisout
转载请注明：http://www.cbpxw.com/hbzz/10328.html
